Arcalyst (rilonacept) — United Healthcare

Initial criteria

• Diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
• AND disease is in remission (e.g., diary score of < 0.5 [reflecting no fever, skin rash and bone pain], acute phase reactants [<0.5 mg/dL CRP], absence of objective skin rash, no radiological evidence of active bone lesions)

Reauthorization criteria

• Documentation of positive clinical response to Arcalyst therapy

Approval duration

12 months